- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Nephrology
Volume 2014 (2014), Article ID 326163, 5 pages
Peritoneal Equilibration Test in Costa Rica: Discrepancies from Other Populations
1Department of Nephrology, Hospital San Juan de Dios, 11501-2060 San José, Costa Rica
2Department of Pharmacology, University of Costa Rica, 11501-2060 San José, Costa Rica
Received 26 August 2013; Revised 18 October 2013; Accepted 18 October 2013; Published 2 January 2014
Academic Editor: Jaime Uribarri
Copyright © 2014 Marta Avellan-Boza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. Continuous Ambulatory Peritoneal Dialysis (CAPD) is a kidney replacement therapy that has been recently incorporated in developing countries. We aim to establish our reference values, to compare them with the original and the Mexican population, and to associate some variables with the type of peritoneal transport. Methods. Thirty peritoneal equilibration tests (PET) were performed. The ratio for D/P creatinine and the D/D0 ratio for glucose were calculated and compared to reference values. We conducted a retrospective analysis to correlate peritoneal transporters with some predictive variables. Results. D/P creatinine ratio at 2 hours, D/D0 glucose ratio at 4 hours, and net ultrafiltrate volume (nUFV) were significantly different from those reported by Twardowski et al. The results documented in the Mexican population only coincide with our results for the D/P creatinine ratio at 4 hours. Any of the studied variables were associated with a specific type of peritoneal transport. Conclusions. Peritoneal permeability among Costa Rican CAPD patients is different from the original population described by Twardowski et al. and from other Latin-American population. This supports the theory that ethnical differences could be responsible for such variations and they validate our statement that each region should possess value references of their own.
In Costa Rica, continuous ambulatory peritoneal dialysis (CAPD) was introduced in the late eighties, initially with few patients as a short-term renal replacement therapy. Currently, social security covers around one hundred fifty adult patients (2/3 of which are men) distributed in four main hospitals around the country.
Patients undergoing CAPD exhibit a wide variability in the peritoneal transport of solutes and fluids. Measuring the characteristics of peritoneal membrane transport is important for the characterization of the functional state as for the prescription of the adequate dose of dialysis therapy in an individual fashion [1, 2]. The peritoneal equilibration test (PET) is the most widely used method to characterize and classify the peritoneal transport of patients on dialysis, and their methodology was standardized by Twardowski et al. [2, 3] more than two decades ago. The PET characterizes the peritoneal membrane transport properties by determining the ratio of the creatinine concentration in the dialysate to that in the plasma after a 4 h dwell (D/Pc) and has been shown to vary considerably among individuals. However, even if the results are highly consistent in the same individual, great variability has been seen among patients . The PET is an easy and inexpensive test and it provides valuable information about peritoneal clearance of solutes and ultrafiltration. Peritoneal transport type classification is broadly recognized not only as aid for prescription but also as a prognostic index since previous analyses have indicated that a higher rate of peritoneal membrane solute transport is associated with increased mortality in peritoneal dialysis patients .
In our country an adequate characterization of the type of peritoneal transport has not been done yet. Our population presents marked ethnic differences as compared with those for which the test was described. In previous studies significant differences have been found in reference values for D/D0 glucose and D/P creatinine for different populations using the same standardized PET [6–8].
For these reasons, we aim to establish the reference values for the Costa Rican population and to determine the influence of different clinical factors on the type of peritoneal transport.
2. Subjects and Methods
The standardized Twardowski et al.  PET was performed in thirty consecutive adult outpatients belonging to the CAPD program at San Juan de Dios Hospital, San José, Costa Rica, in the period between August and October of 2012. Patients that presented with peritonitis in the last 4 weeks or that had less than 4 weeks since placement of the catheter were excluded.
Following the night exchange and 8–12 hours of dwell time, the totality of the abdominal cavity was drained and new exchange was introduced with 2 liters of glucose 4.25% peridial solution this was performed in the supine position and mobilizing the patient every 2 minutes to insure an adequate mixture of the dialysate solution in the abdominal cavity. Shortly after, dialysis solution samples and blood samples were taken at 0, 2, and 4 hours. After 4 hours, the dialysate solution was drained and its volume was quantified. Glucose, creatinine, C reactive protein, and albumin were measured in each sample, using conventional techniques with a colorimetric assay. There was no need to use are a correction factor for creatinine in the peritoneal fluid, because it was proven that its quantification with the equipment used is zero, in spite of the high glucose concentrations in a new peridial solution bag .
Using our own values for D/P creatinine, a patient was classified as a high transporter if his D/P is 1 standard deviation (SD) above the mean (0.78); as high-average if his D/P is between the mean and +1 SD (0.66–0.78); as low-average if his D/P is between the mean −1 DS (0.54–0.65); and it was classified as low transporter if his D/P is found below −1 DS (0.53) [1, 2]. The study protocol and consent form were approved by the local institutional review board and ethics committee. All subjects or an appropriate surrogate provided written informed consent before any study-related procedure was completed.
A sample size of thirty patients was calculated with the objective of determining the proportion of average transporters (high and low), with an 18% of precision. We took as reference an expected proportion of average transporters of 68%, as suggested by previous studies .
The data is presented as mean SD or percentages. The comparisons between our results and those reported by Twardowski et al.  and by Cueto-Manzano et al.  were made through the Student’s t test for independent samples. The comparisons between the type of transporters according to the D/P creatinine and D/D0 glucose were made by the ANOVA test, square chi test, or by the exact Fisher test according to the type of variable. We decided to measure only the D/P creatinine and D/D0 glucose rates because these are the most useful indexes to predict patient responses to peritoneal dialysis according to Twadorsky et al. .
A value ofless than 0.05 was considered as significant. All statistical analyses were carried out using SPSS 20.0 for Windows (Chicago, Illinois).
The characteristics of the population studied are represented in Table 1. In average, the cohort was mainly composed by men whose therapy time varied between 8.6 and 154 weeks, with a mode of 52 weeks. None of these variables was statistically related with any type of peritoneal transport, neither with the presence of peritonitis nor diabetes mellitus (Table 2).
The comparisons of the PET values obtained by D/P creatinine and by D/D0 glucose at 2 and 4 hours in our population and those obtained in the original population by Twardowski et al.  and by Cueto et al.  are shown in Table 3. The results of D/D0 glucose at 4 hours, of D/P creatinine at 2 hours and the ultrafiltrate volume are different in our population than those found in the population studied by Twardowski and colleagues. The results documented in the Mexican population only coincide with our results for the D/P creatinine values obtained at 4 hours.
In Latin America very few studies have been made to validate the PET in this region. PET is a feasible technique used to tailor the CAPD prescription and a very important tool to predict poor outcomes. Since much variability has been observed in the PET results, it is recommended to perform this test early in treatment in each CAPD Unit .
If our sample were categorized according to the reference values provided by Twadorski et al. , the classification of our cohort would be changed. The population distribution, according to our values, would vary with respect to those found by Twardowski, since, according to our curves, a 16.6% are low transporters, 36.6% are low-average transporters, 36.6% are high-average transporters, and around 10% are high transporters. If they were classified in accordance with the original population the distribution would be 10% low transporters, 46.7% low-average transporters, and 43.3% high-average transporters, hence, no patient would be classified as a high transporter.
Besides, in comparison with the Mexican cohort, our sample exhibited a lower creatinine D/P ratio at 0 hours. This can be the result of heterogeneous residual dialysate volumes. However, neither the Mexican study nor our research determined this volume and proper conclusion could not be drawn. Similarly, glucose D/D0 ratios at 2 and 4 hours were lower in our cohort than in the Mexican and original population. This result may be due to high dialysate glucose absorption as well as a consequence of eventual errors in nursing procedures or laboratory measurements.
We must highlight that the composition of each compared population was different. Sixty-three percent of our sample was diabetic and one third of our patients had a history of peritonitis. Both of these variables were significantly different in our sample and can also explain our findings. Several studies, with conflicting results, have revealed histopathological alterations in the peritoneal membrane of diabetic patients leading to increased glucose absorption [3, 4]. Furthermore, patients with past peritonitis also exhibit high values of monocyte chemoattractant protein-1 (MCP-1) resulting in increased peritoneal membrane permeability .
It is remarkable that the ultrafiltrate volume is one of the variables that differ in a greater magnitude, both in the original population and in the Mexican cohort, since the volume variable was larger in our sample. This is not in concordance with our findings of D/D0 for glucose, which is significantly smaller at 4 hours and indicates larger glucose absorption from the dialysis solution. It suggests that other nonosmotic stimuli can explain how the ultrafiltrate volume independently varies from the glucose concentration of the dialysate. In animal models, it has been suggested that 50% of the transperitoneal water flow occurs through ultrasmall pores, known as aquaporins 1 whose expression is not completely related with osmotic stimuli [1, 12].
It is important to note that in comparison with the original and Mexican population we used a 4.25% dextrose solution instead of the 2.5% dextrose exchange. Although previous findings have determined that D/D0 glucose and D/P creatinine are similar with the use of either 4.25% or 2.5% solution, these studies have also shown that using a 4.25% dextrose solution produce higher drained volumes than the 2.5% dextrose exchange . Hence, disparities in drained volumes can also be explained as a consequence of different dialysis solutions.
Although differences in body mass composition (due to the majority of men in our sample or secondary to ethnic differences) can explain our results, the actual evidence regarding this issue is inconclusive. Previous investigations have shown the relationship between large body surface area and high D/P creatinine , while other studies have reported a null effect . Besides, the high proportion of men patients in our cohort reflects the Costa Rican peritoneal dialysis population, with almost two-thirds of patients being male.
Although we did not determine any genetic factor that explains the variability among the three cohorts, several gene polymorphisms in the vascular endothelial growth factor (VEGF) gene, endothelial nitric oxide synthase gene (ENOS), and interleukin 6 (IL-6) gene have been correlated with the interpatient variability in PET results . Further studies must test this hypothesis in order to identify genetic variants that explain these differences among populations.
In this study there were no significant differences between age, gender, diabetes mellitus, serum albumin, C reactive protein, and the type of peritoneal transport, even when previous studies have revealed a higher proportion of men, diabetic patients, and low serum albumin concentration in the high transporter group [1, 17]. These conflicting results can be the consequence of the different threshold to define high average transporters in our sample, as well as an under representativeness of these subgroups.
Studies performed in other latitudes show different reference ranges for the classification of the types of peritoneal transport. The PET results of this study differ from the values described originally by Twardowski et al. and from other Latin American population. As a consequence of these discrepancies, we consider that CAPD prescription in our country should be made based on the presented reference values.
Our findings support the theory that different ethnical factors can be responsible for such variations and it validates the affirmation that each region should possess its own reference values.
|CAPD:||Continuous ambulatory peritoneal dialysis|
|PET:||Peritoneal equilibration test.|
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
The authors acknowledge their gratitude to the staff of the Dr. Luis Guillermo Brenes-Sobrado Nephrology Laboratory and to the registered nurses: Delia Gómez-Gómez and Carolina Méndez-Carvajal from the Chronic Ambulatory Peritoneal Dialysis Program of the San Juan de Dios Hospital, San José, Costa Rica.
- V. La Milia, “Peritoneal transport testing,” Journal of Nephrology, vol. 23, no. 6, pp. 633–647, 2010.
- O. Devuyst, P. J. Margetts, and N. Topley, “The pathophysiology of the peritoneal membrane,” Journal of the American Society of Nephrology, vol. 21, no. 7, pp. 1077–1085, 2010.
- Z. J. Twardowski, K. D. Nolph, R. Khanna et al., “Peritoneal equilibration test,” Peritoneal Dialysis Bulletin, vol. 7, no. 3, pp. 138–147, 1987.
- A. M. Cueto-Manzano, A. Díaz-Alvarenga, and R. Correa-Rotter, “Analysis of the peritoneal equilibration test in Mexico and factors influencing the peritoneal transport rate,” Peritoneal Dialysis International, vol. 19, no. 1, pp. 45–50, 1999.
- K. S. Brimble, M. Walker, P. J. Margetts, K. K. Kundhal, and C. G. Rabbat, “Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis,” Journal of the American Society of Nephrology, vol. 17, no. 9, pp. 2591–2598, 2006.
- R. Dwarakanathan, H. Z. Yaakob, and H. Hadi, “Pattern of peritoneal permeability in continuous ambulatory peritoneal dialysis patients in Brunei,” Peritoneal Dialysis International, vol. 23, no. 2, pp. S11–S13, 2003.
- J. Al-wakeel, M. Al-Ghonaim, A. Al-Suwaida et al., “Peritoneal membrane characteristics in patients on peritoneal dialysis,” Saudi Journal of Kidney Diseases and Transplantation, vol. 22, no. 1, pp. 49–53, 2011.
- E. Rojas-Campos, H. R. Martínez-Ramírez, L. Cortés-Sanabria, et al., “The peritoneal transport type might be distinctive among different Mexican populations on CAPD,” Revista de Investigacion Clinica, vol. 60, pp. 284–291, 2008.
- M. Wilkie and J. Wild, “Peritoneal equilibration testing: correcting the correction factor,” Peritoneal Dialysis International, vol. 29, no. 3, pp. 352–355, 2009.
- P. G. Blake, J. M. Bargman, K. S. Brimble et al., “Clinical practice guidelines and recommendations on peritoneal dialysis adequacy 2011,” Peritoneal Dialysis International, vol. 31, no. 2, pp. 218–239, 2011.
- A. R. Malik, M. A. Little, M. Henriksson, F. W. K. Tam, and E. A. Brown, “Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis,” Journal of Nephrology, vol. 20, no. 3, pp. 340–349, 2007.
- C. Ronco, M. Feriani, S. Chiaramonte et al., “Pathophysiology of ultrafiltration in peritoneal dialysis,” Peritoneal Dialysis International, vol. 10, no. 2, pp. 119–126, 1990.
- E. T. Pride, J. Gustafson, A. Graham et al., “Comparison of a 2.5% and a 4.25% dextrose peritoneal equilibration test,” Peritoneal Dialysis International, vol. 22, no. 3, pp. 365–370, 2002.
- A. Díaz-Alvarenga, M. Abasta-Jimenez, B. Bravo, G. Gamba, and R. Correa-Rotter, “Serum albumin and body surface area are the strongest predictors of the peritoneal transport type,” Advances in Peritoneal Dialysis, vol. 10, pp. 47–51, 1994.
- A. H. Tzamaloukas, G. H. Murata, B. Piraino et al., “The relation between body size and normalized small solute clearances in continuous ambulatory peritoneal dialysis,” Journal of the American Society of Nephrology, vol. 10, no. 7, pp. 1575–1581, 1999.
- G. Gillerot, E. Goffin, C. Michel et al., “Genetic and clinical factors influence the baseline permeability of the peritoneal membrane,” Kidney International, vol. 67, no. 6, pp. 2477–2487, 2005.
- D. N. Churchill, K. E. Thorpe, K. D. Nolph, P. R. Keshaviah, D. G. Oreopoulos, and D. Pagé, “Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients,” Journal of the American Society of Nephrology, vol. 9, no. 7, pp. 1285–1292, 1998.